Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

Quotient Bioresearch Scoops Up Charles River Laboratories’ Edinburgh Clinical Research Facility

  • Quotient Bioresearch acquired Charles River Laboratories’ Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient.

    The Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form Quotient Clinical, a new strategic business unit within Quotient.

    Quotient Clinical will have a workforce of approximately 160 medical, scientific, and clinical staff across the two facilities in Edinburgh and Nottingham. The new division will provide early development services to a broad range of pharmaceutical and biotechnology customers. Mark Egerton, formerly CEO of Pharmaceutical Profiles, will head the new business unit.

    “The creation of Quotient Clinical represents the next step in expanding the range of specialized services we offer,” reports Paul Cowan, chairman and CEO of Quotient.

    In addition to the Charles River facility and Pharmaceutical Profiles, Quotient has acquired HFL, BioDynamics Research, GR Micro, and Alba Bioscience since January 2007.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »